OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
A landscape analysis and discussion of value of gene therapies for sickle cell disease	48
Adherence to augmentation therapy for the treatment of major depressive disorder	38
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	26
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	23
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	20
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	20
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	18
The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature	17
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain	16
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	15
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care	15
The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study	14
Social care data in the UK; current landscape, challenges, and future recommendations	13
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients	13
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial	12
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia	12
Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review	11
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	11
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	10
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	10
The cost-of-illness of multiple sclerosis in Jordan	10
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	10
Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia	9
Addressing racial/ethnic disparities associated with Medicare Part D Star Ratings among population with Alzheimer’s disease and related dementias	9
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	9

Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review	9
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	9
How to create value with constrained budgets in oncological care? A narrative review	9
Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?	9
Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database	8
Cost-effectiveness of hysterectomy, first- and second-generation endometrial ablation, and levonorgestrel-releasing device for treatment of heavy menstrual bleeding: a systematic review	8
Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review	8
Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population	8
Challenges and opportunities in measuring the pediatric quality of life: exemplified by research in pediatric gastroenterology	8
The hidden burden of atopic dermatitis in central and Eastern European countries	8
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	7
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China	7
Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review	7
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	7
Hospital care of endometriosis in Spain: a retrospective multicenter analysis of patient characteristics and costs	7
Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study	7
A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis	7
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US	7
A comparison of six approaches for measuring utility values among patients with locally advanced cervical cancer	7
Evaluating the correlations of cost and utility parameters from summary statistics for probabilistic analysis in economic evaluations	7
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	6
Economic evaluation of interventions to improve medication adherence among patients with chronic diseases: an overview of systematic reviews	6
Early economic evaluation of an intervention to improve uptake of the NHS England Diabetes Prevention Programme	6
Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece	6
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain	6
Content and cost of waste pharmaceuticals collected by pharmacies for disposal	6
Disparities in Respiratory Syncytial Virus Risk Factors, Diagnosis, and Outcomes in Adults by Race, Ethnicity, and Other Social Determinants of Health in the United States	6
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?	6
Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer	6
Economic benefits of global Collaborative Health technology	5
Overview and quality assessment of health economic evaluations for homeopathic therapy: an updated systematic review	5
Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency	5
Not cost-effective at zero price: valuing and paying for combination therapies in cancer	5
Nonadherence to antiseizure medications: what have we learned and what can be done next?	5
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	5
Interview with Julie Frappier, health economist, and creator of the TOWWERS™ System	5
Assessing the economic impact of digital endpoints on medication adherence	5
A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden	5
Natural language processing – relevance to patient outcomes and real-world evidence	5
Can we achieve affordable cancer medicine prices? Developing a pathway for change	4
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China	4
What to expect in 2024: important health economics and outcomes research (HEOR) trends	4
Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension	4
Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer	4
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	4
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	4
An early cost analysis of magnetic bone growth stimulation in England	4
Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia	4
Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia	4
Distinguishing features in the assessment of mHealth apps	4

How unprofessional behaviours between healthcare staff threaten patient care and safety	4
Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis	4
The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran	4
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	4
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	4
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A	4
Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications	4
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	4
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study	4
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority	4
The utility and impact of digital endpoints for improving breast cancer outcomes	4
Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US	4
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	4
Value-based performance arrangements for chronic conditions: an economic simulation of Medicaid Drug Rebate Program reforms	4
A visual approach to the economic evaluation of vaccines: opening the health economic black box	4
Psychometric properties of the Polish version of SF-12v2 in the general population survey	3
Health-related quality of life measured using the EQ-5D-3L: iranian population norms	3
A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury	3
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review	3
Budgetary impact analysis of alteplase - recombinant tissue plasminogen activator (rtPA) - as a thrombolytic treatment for acute ischemic stroke in Colombia	3
Comparing measurement properties of EQ-5D and SF-6D in East and South-East Asian populations: a scoping review	3
The cost-effectiveness of using rapid diagnostic tests for the diagnosis of typhoid fever in patients with suspected typhoid fever: a systematic review	3
Measuring valued output in primary care: challenges and reconciliation	3
An early health technology assessment of 3D anatomic models in pediatric congenital heart surgery: potential cost-effectiveness and decision uncertainty	3
Consumption of antidepressants and economic austerity in Brazil	3
Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review	3
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach	3
Assessment of women’s treatment preferences for vasomotor symptoms due to menopause	3
Tackling reimbursement challenges to fair access to medicines – introduction to the topic	3
The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma	3
Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?	3
What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States	3
Economic burden of type-2 diabetes in Peru: a cost-of-illness study valuing cost differences associated with the level of glycemic control	3
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	3
Canadian French translation and linguistic validation of the health-related quality of life utility measure for pre-school children	3
Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil	3
Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus	3
Value attributes of advanced therapy medicinal products: a documentary analysis of comments received from stakeholders during reimbursement decisions to England’s National Institute of Health and Care	3
Seeing the whole elephant: integrated advanced data analytics in support of RWE for the development and use of innovative pharmaceuticals	3
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer	3
Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument	3
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis	3
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	3
Evaluation instruments for executive functions in children and adolescents: a systematic review	3